CHIASMA, INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | — | — | — | — | — |
| Operating income | −$15.7M | −$8.9M | −$32.3M | −$28.1M | −$61.3M | −$35.4M |
| Net income | −$15.4M | −$8.8M | −$31.3M | −$26.8M | −$61.1M | −$35.9M |
| Total assets | $176.3M | $98.8M | $63.3M | $69.9M | $96.8M | $153.1M |
| Total liabilities | $84.6M | $13.1M | $29.1M | $7.4M | $11.0M | $10.3M |
| Equity | $91.8M | $85.8M | $34.1M | $62.5M | $85.7M | $142.8M |
| EPS (diluted) | $-0.36 | $-0.36 | $-1.28 | $-1.10 | $-2.51 | $-3.25 |
| Shares out. | 42.3M | 24.5M | 24.4M | 24.4M | 24.3M | 24.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −1420.2%
- Net margin
- −1391.1%
- Return on equity
- −16.8%
- Return on assets
- −8.7%
- Return on capital (ROCE)
- −9.8%
- Liabilities / assets
- 47.9%
- Debt / equity
- 0.92×
- Book value / share
- $2.17
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -0.80distress
- Accruals / assets
- 34.0%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventAug 5, 2021
- Shareholder voteAug 3, 2021
- Other material eventJul 2, 2021
- Other material eventJun 22, 2021
- Entered a material agreement · Other material eventMay 5, 2021
- Results of operationsMay 5, 2021
- Other material eventMay 5, 2021
- Results of operationsMar 4, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 15, 2022
- EFFECTAug 11, 2021
- 15-12BAug 11, 2021
- 4FORM 4Aug 9, 2021
- SC 13G/AAug 9, 2021
- S-8 POSAug 6, 2021
- S-8 POSAug 6, 2021
- S-8 POSAug 6, 2021
- S-8 POSAug 6, 2021
- S-8 POSAug 6, 2021
- POS AMAug 6, 2021
- 4FORM 4 SUBMISSIONAug 5, 2021
- 4FORM 4 SUBMISSIONAug 5, 2021
- 4FORM 4 SUBMISSIONAug 5, 2021
- 4FORM 4 SUBMISSIONAug 5, 2021